Baker BROS. Advisors LP Buys 51,000 Shares of vTv Therapeutics Inc. $VTVT

Baker BROS. Advisors LP increased its stake in shares of vTv Therapeutics Inc. (NASDAQ:VTVT) by 52.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 148,314 shares of the biotechnology company’s stock after purchasing an additional 51,000 shares during the quarter. Baker BROS. Advisors LP’s holdings in vTv Therapeutics were worth $3,463,000 at the end of the most recent quarter.

vTv Therapeutics Price Performance

VTVT opened at $33.28 on Friday. The firm has a 50 day simple moving average of $35.93 and a 200 day simple moving average of $29.51. vTv Therapeutics Inc. has a fifty-two week low of $14.00 and a fifty-two week high of $44.00. The company has a market cap of $131.12 million, a price-to-earnings ratio of -9.93 and a beta of 0.44.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings data on Tuesday, March 10th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.51. The business had revenue of ($0.02) million during the quarter.

Key Headlines Impacting vTv Therapeutics

Here are the key news stories impacting vTv Therapeutics this week:

• Positive Sentiment: Evercore ISI initiated coverage with an “Outperform” recommendation, providing a new institutional buy-side endorsement that can attract demand and support the share price. Evercore initiation article
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and $47 price target while raising several near-term EPS estimates (Q1–Q4 2026 and FY2026) and trimming losses for FY2027 relative to prior forecasts — a signal that the firm sees improving fundamentals in the nearer term and provides supportive analyst cover (no link available).
• Neutral Sentiment: vTv filed Q4 and full-year 2025 financial results and issued a corporate update; company results and commentary can influence sentiment depending on guidance and program milestones, so investors should review the release for pipeline/cash details. Q4/FY2025 results and corporate update
• Neutral Sentiment: Market calendars show vTv is projected to announce upcoming earnings — scheduled event risk can increase intraday volatility around the stock. Earnings projection article
• Negative Sentiment: Within the same HC Wainwright coverage notes, the firm lowered long‑range EPS assumptions (FY2028–FY2030 and FY2029 reductions), increasing projected longer-term losses. Those cuts could pressure expectations for longer-term profitability and cap upside despite near-term improvements (no link available).

Analysts Set New Price Targets

VTVT has been the subject of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of vTv Therapeutics in a research report on Monday, December 29th. TD Cowen assumed coverage on vTv Therapeutics in a research report on Monday, January 5th. They issued a “buy” rating on the stock. Wall Street Zen raised vTv Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Evercore began coverage on vTv Therapeutics in a research note on Thursday. They set an “outperform” rating and a $44.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $47.00 price target (up from $36.00) on shares of vTv Therapeutics in a report on Friday, December 19th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, vTv Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $53.00.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.